Gene · 2176
Papers2,586
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
821 to 840 of 2,586
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Genomic Landscape of Chinese Clear Cell Renal Cell Carcinoma Patients With Venous Tumor Thrombus Identifies Chromosome 9 and 14 Deletions and Related Immunosuppressive Microenvironment. | Front Oncol | 2021 | 34249685 | PubTator, text mining | PubMed |
| Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. | Ann Oncol | 2021 | 34242744 | PubTator, text mining | PubMed |
| Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. | J Clin Transl Res | 2021 | 34239995 | PubTator, text mining | PubMed |
| Highlights of the 17th St Gallen International Breast Cancer Conference 2021: customising local and systemic therapies. | Ecancermedicalscience | 2021 | 34221119 | PubTator, text mining | PubMed |
| DNA Repair Gene Polymorphisms and Chromosomal Aberrations in Exposed Populations. | Front Genet | 2021 | 34220964 | PubTator, text mining | PubMed |
| Targeting the replication stress response through synthetic lethal strategies in cancer medicine. | Trends Cancer | 2021 | 34215565 | PubTator, text mining | PubMed |
| Identification of germline cancer predisposition variants during clinical ctDNA testing. | Sci Rep | 2021 | 34211039 | PubTator, text mining | PubMed |
| Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families. | J Pers Med | 2021 | 34204722 | PubTator, text mining | PubMed |
| A Multidisciplinary Approach to Evaluate the Presence of Hepatic and Cardiac Abnormalities in Patients with Post-Acute COVID-19 Syndrome-A Pilot Study. | J Clin Med | 2021 | 34204032 | PubTator, text mining | PubMed |
| Targeted Sequencing of Taiwanese Breast Cancer with Risk Stratification by the Concurrent Genes Signature: A Feasibility Study. | J Pers Med | 2021 | 34203389 | PubTator, text mining | PubMed |
| PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening. | Biomedicines | 2021 | 34203351 | PubTator, text mining | PubMed |
| BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer. | Genes (Basel) | 2021 | 34201956 | PubTator, text mining | PubMed |
| Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer. | Cancers (Basel) | 2021 | 34201502 | PubTator, text mining | PubMed |
| Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing. | Int J Mol Sci | 2021 | 34200975 | PubTator, text mining | PubMed |
Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis. | Cancers (Basel) | 2021 | 34199565 | PubTator, text mining | PubMed |
| DNA Damage Repair Gene Set as a Potential Biomarker for Stratifying Patients with High Tumor Mutational Burden. | Biology (Basel) | 2021 | 34198473 | PubTator, text mining | PubMed |
| EXO5-DNA structure and BLM interactions direct DNA resection critical for ATR-dependent replication restart. | Mol Cell | 2021 | 34197737 | PubTator, text mining | PubMed |
| A novel classification of hematologic conditions in patients with Fanconi anemia. | Haematologica | 2021 | 34196171 | PubTator, text mining | PubMed |
| Genome editing to define the function of risk loci and variants in rheumatic disease. | Nat Rev Rheumatol | 2021 | 34188205 | PubTator, text mining | PubMed |
| Deletion of a pseudogene within a fragile site triggers the oncogenic expression of the mitotic CCSER1 gene. | Life Sci Alliance | 2021 | 34187875 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2176/papers?page=42